Natco Pharma Reports Strong December Quarter Results And Announces Dividend

Leadership Update  
Natco Pharma announced the re-appointment of Rajeev Nannapaneni, reinforcing continuity in leadership. His role is expected to further strengthen the company’s strategic direction and growth initiatives in the pharmaceutical sector.  

Quarterly Performance  
The company reported consolidated revenue of 6.47 billion rupees, supported by strong demand across its product portfolio. Net profit of 1.52 billion rupees reflects healthy margins and efficient operations, underscoring resilience in a competitive market.  

Dividend Declaration  
Natco Pharma declared a dividend of 1.50 rupees per share, signaling confidence in its financial stability and commitment to rewarding shareholders. This move highlights the company’s focus on balancing growth with investor returns.  

Market Outlook  
With a strong leadership team and robust financial performance, Natco Pharma is positioned to expand its presence in domestic and international markets. Continued focus on innovation and cost efficiency will drive future growth.  

Key Highlights  

• Consolidated revenue from operations at 6.47 billion rupees  
• Net profit reported at 1.52 billion rupees  
• Dividend declared at 1.50 rupees per share  
• Re-appointment of Rajeev Nannapaneni  
• Strong demand across pharmaceutical portfolio  

Conclusion  
Natco Pharma’s December quarter results reflect solid growth, leadership stability, and shareholder value creation. With a renewed focus on innovation and efficiency, the company is well-placed to sustain momentum in the pharmaceutical industry.  

Sources: Reuters, Economic Times, Business Standard